Transdermal Or Percutaneous Patents (Class 424/449)
-
Publication number: 20130331803Abstract: The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.Type: ApplicationFiled: November 17, 2010Publication date: December 12, 2013Applicant: HEXAL AGInventors: Jens Fleschhut, Susanne Feinaeugle, Karin Lauer
-
Patent number: 8597667Abstract: A system and methods are provided for targeted and individualized delivery of multiple skin benefit agents to the skin of a user. The image of a predetermined treatment area of the user's skin is first captured by an imaging device. The captured image data is then analyzed by a computing device to generate a unique skin profile for the user. Based on such skin profile, a printing device prints out one or more cosmetic delivery sheets that can be applied to the predetermined treatment area. Each of the cosmetic delivery sheets contains a substrate with multiple isolated, discrete regions, while at least two of the regions are imprinted with different skin benefit agents for treating different skin conditions of the predetermined treatment area according to the unique skin profile of the user.Type: GrantFiled: March 24, 2009Date of Patent: December 3, 2013Assignee: ELC Management LLCInventors: Tsung-Wei Robert Mou, Fatemeh Mohammadi, Lisa Qu, Tamar Lara Kamen, Anna Czarnota
-
Patent number: 8591940Abstract: A method of treating scar tissue by applying a composite sheet for delivering therapeutic agents to the skin is disclosed. The composite sheet comprises a flexible porous polymer for holding and releasing the therapeutic agent in a polymer enrobing material. Microchannels pass through the polymer enrobing material and flexible porous polymer to promote the release of the therapeutic agent. The composite sheet is capable of releasing the therapeutic agent for periods of about 0 to about 30 days.Type: GrantFiled: December 20, 2007Date of Patent: November 26, 2013Assignee: New Medical Technology Inc.Inventors: Haitham Matloub, Wilfred Lynch
-
Patent number: 8591941Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.Type: GrantFiled: August 4, 2011Date of Patent: November 26, 2013Assignee: Noven Pharmaceuticals, Inc.Inventors: David Kanios, Juan A. Mantelle, Viet Nguyen
-
Patent number: 8586079Abstract: A promotional insert for advertising a transdermal patch to a reader of a periodical comprising a sample of the transdermal patch attached to the promotional insert, wherein the promotional insert contains a description of the sample of the transdermal patch attached thereto, and wherein the promotional insert is suitable for inclusion into a periodical. A process for producing the promotional insert, and a use of the promotional insert in a magazine for advertisement of the transdermal patch are also described.Type: GrantFiled: June 21, 2002Date of Patent: November 19, 2013Assignee: Graphic Productions Inc.Inventors: Kenneth W. Hansted, David Sanders, Philip Welsher
-
Patent number: 8586080Abstract: Compositions and methods for the continuous and controlled transdermal delivery of an active agent from a pharmaceutically acceptable carrier composition comprising a polyoxazoline polymer, wherein the active drug incorporated in the carrier composition of the transdermal system remains substantially solubilized and stable during storage prior to use.Type: GrantFiled: October 28, 2004Date of Patent: November 19, 2013Assignee: Noven Pharmaceuticals, Inc.Inventors: Rod Hartwig, David Kanios
-
Patent number: 8580281Abstract: Provided is a medicated patch containing a medicinal agent and an adhesive base material and having an acid value of no greater than 28, where the medicinal agent is varenicline or a pharmaceutically acceptable salt of varenicline.Type: GrantFiled: February 9, 2009Date of Patent: November 12, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kumi Morimoto, Akio Takeuchi, Takashi Yasukochi, Kaori Yamaguchi, Kenji Ishigaki
-
Patent number: 8568740Abstract: This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and/or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and/or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin. The compositions may further contain molecules that are not native to botulinum toxin and that bind non-covalently to the botulinum toxin complexes, thereby acting as skin-tropic “adhesion molecules” to improve the ability of the toxin complexes to adhere to and to penetrate the skin epithelium. The compositions have an improved safety profile compared to existing botulinum-containing compositions that are injected subcutaneously. Methods for the use of such compositions are also contemplated by this invention.Type: GrantFiled: November 16, 2006Date of Patent: October 29, 2013Assignee: Revance Therapeutics, Inc.Inventor: Jacob M. Waugh
-
Patent number: 8568770Abstract: There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof.Type: GrantFiled: November 20, 2009Date of Patent: October 29, 2013Assignee: Lead Chemical Co., Ltd.Inventors: Takayasu Matsuzawa, Tamaki Horiuchi, Seijiro Yama, Sunao Takeuchi, Makoto Takeuchi
-
Patent number: 8568746Abstract: Disclosed is a transdermal composition, which uses high-purity phosphatidylcholine that is most susceptible to oxidation and the like, and which exhibits high stability and high migration into the skin. Specifically, a transdermal composition having good stability and migration into the skin is able to be obtained by preparing a transdermal composition (a colloidal dispersion liquid of phosphatidylcholine) that contains high-purity phosphatidylcholine, carnitine, a polyhydric alcohol and water. Since the transdermal composition does not contain an oleaginous base (an oil component), the transdermal composition has skin compatibility and is thus useful as a therapeutic agent or a cosmetic preparation. In addition, phosphatidylcholine and carnitine have an effect of achieving good migration into the skin and are capable of promoting systemic or local lipid metabolism in subcutaneous adipose tissues.Type: GrantFiled: May 21, 2010Date of Patent: October 29, 2013Assignee: MEDRx Co., Ltd.Inventors: Keiko Yamasaki, Takahiro Tanimoto
-
Patent number: 8563031Abstract: This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in this instance, piroxicam.Type: GrantFiled: May 25, 2011Date of Patent: October 22, 2013Assignee: Absize, Inc.Inventors: Changjin Wang, Eric Y. Sheu, Nancy Vuong
-
Patent number: 8557279Abstract: The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.Type: GrantFiled: September 6, 2011Date of Patent: October 15, 2013Assignee: Bayer Intellectual Property GmbHInventors: Stefan Bracht, Ildiko Terebesi, Thomas Langguth
-
Patent number: 8551516Abstract: The present invention provides compositions, methods, and kits for improving health in a woman having elevated SHBG levels, or who is receiving oral estrogen supplementation, by non-orally administering an effective amount of an androgenic steroid. Further, the present invention provides compositions, methods, and kits for coadministering an effective amount of an orally administered estrogen and an effective amount of a non-orally administered androgenic steroid for women in need of estrogen supplementation.Type: GrantFiled: February 15, 2007Date of Patent: October 8, 2013Assignee: Actavis, Inc.Inventors: Theresa Rosario-Jansen, Norman A. Mazer
-
Patent number: 8545873Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.Type: GrantFiled: March 13, 2012Date of Patent: October 1, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Patent number: 8545872Abstract: The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(?)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(?)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ?m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.Type: GrantFiled: February 3, 2011Date of Patent: October 1, 2013Assignee: UCB Pharma GmbHInventor: Armin Breitenbach
-
Patent number: 8541022Abstract: A method of treating a superficial or partial thickness burn caused by heat, or by UV or laser radiation is disclosed. The method includes topically applying a topical composition containing an avermectin compound to an affected area immediately after a burn occurs. The method further includes cooling the affected area with ice or water prior to application of the topical composition. Additionally, the method includes topically applying a second topical composition containing fluocinonide and salicylic acid on the affected area to further enhance anti-inflammatory effect of the avermectin compound on the damaged skin.Type: GrantFiled: June 2, 2008Date of Patent: September 24, 2013Assignee: Galderma S.A.Inventors: L. Dean Parks, Jeffrey D. Parks
-
Patent number: 8535650Abstract: The invention relates to compositions and methods for drug delivery suitable for promoting the transmucosal absorption of drugs, especially drugs with poor intrinsic bioavailability, such as peptides, proteins, vaccines, and nucleic acids. The delivery system of this invention preferably comprises fatty acid esters and their hydrophilic derivatives that associate with water and other polar solvents to form reverse micelles that are physically stabilized in the presence of gastrointestinal fluid, water, and other hydrophilic solvents. Such stable reverse micelles are formed by suitable mixtures of polymeric or non-polymeric compounds with amphiphiles. Micelles made using these methods undergo phase transformation more slowly resulting in delayed drug release profiles and sustained absorption.Type: GrantFiled: December 3, 2002Date of Patent: September 17, 2013Assignee: Soligenix, Inc.Inventors: Panayiotis P. Constantinides, Likan Liang, Eun-Hyun Jang
-
Patent number: 8535711Abstract: The potential for environmental release of unused and expired medications is reduced by the provision of a system and method for combining the unused or expired medication with an amount of activated carbon as part of a disposal procedure.Type: GrantFiled: March 26, 2009Date of Patent: September 17, 2013Assignee: Teikoku Pharma USA, Inc.Inventors: Carter R. Anderson, Russell L. Morris
-
Patent number: 8530424Abstract: A system and method to improve sensory functions in the hand or foot by dermal topical application of a local anaesthetic substance to adjacent skin areas, using a tailored application device or kit specially designed to fit the size and anatomical shape of the body part which is to be anesthetized. The concept is to block sensory input from the anesthetized skin area hereby inducing a functional reorganization in sensory brain cortex resulting in enhanced sensory functions in body parts adjacent to the anesthetized area with focus on the hand and sole of the foot.Type: GrantFiled: September 11, 2008Date of Patent: September 10, 2013Assignee: Ossur HFInventor: Göran Lundborg
-
Patent number: 8524272Abstract: Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween.Type: GrantFiled: August 15, 2003Date of Patent: September 3, 2013Assignee: Mylan Technologies, Inc.Inventor: Kenneth J. Miller, II
-
Patent number: 8524774Abstract: A process for treating psoriasis and similar skin disorders whereby two formulations are used. The first formulation in a cream, gel, lotion, foam or ointment base is used two or more times daily, and contains effective amounts of (but not limited to) methylcobalamin, niacinamide, select cetylated fatty esters, and antioxidants. This formulation is used to suppress immunoproliferative and inflammatory mediated activities that play significant roles in hyperproliferation and erythema. The second formulation, used selectively to reduce plaque thickening and to reduce irritation, contains effective amounts of (but not limited to) salicylic acid and select cetylated fatty esters in a cream, gel, lotion or ointment base, with pH optimized for exfoliation properties. The unique combination of salicylic acid (or other ?- or ?-hydroxy acid) and cetylated fatty esters provides keratolytic activity while suppressing irritation and inflammation.Type: GrantFiled: August 28, 2012Date of Patent: September 3, 2013Assignee: Cymbiotics, Inc.Inventors: Raj R. Barathur, Jack Bain Bookout
-
Patent number: 8524273Abstract: A transdermal absorption preparation having a support and a pressure-sensitive adhesive layer consisting of multiple layers, wherein the pressure-sensitive adhesive layer comprises a drug-retaining layer containing a drug and an acrylic pressure-sensitive adhesive and a skin adhesion layer containing a styrene-isoprene-styrene block copolymer. This preparation can continuously release bisoprolol at a constant concentration. Moreover, it can be easily produced.Type: GrantFiled: February 27, 2007Date of Patent: September 3, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Satoshi Amano, Sachiko Honma, Tetsuro Tateishi, Natsumi Kase
-
Publication number: 20130226061Abstract: Examples of multi-layer bandages and methods for dressing a wound are described. An example multi-layer bandage includes a first layer and second layer and an optional third layer. An exemplary method for dressing a wound may include applying a bandage having a top layer, a middle layer, and a bottom layer to a wound with the bottom layer being provided in contact with the wound, wherein the top layer includes an adhesive for securing the bandage to a surface near the would, and where the bottom layer includes copper; and allowing the bandage to remain over the would for a predetermined period of time. In some examples, the method may further include removing the bottom layer without removing the top and middle layers. In other examples, the method may include removing the bandage when the middle layer or the bottom layer change in color.Type: ApplicationFiled: July 6, 2012Publication date: August 29, 2013Inventor: Richard M. Dickson
-
Patent number: 8506992Abstract: A percutaneous absorption-type pharmaceutical preparation containing a sublimation drug is provided, where from a plaster layer, a drug is released as volatile substance with a lapse of time, but the released drug has no adverse effect on the handling of the preparation, and the quality of the preparation is maintained in storage over a long period of time. A percutaneous absorption-type pharmaceutical preparation, which comprises: a support comprising a plastic film and a nonwoven fabric; and a plaster layer containing a sublimation drug, wherein the plastic film and the nonwoven fabric are laminated with an adhesive having a glass transition temperature of 10° C. or higher, and the plaster layer is laminated on opposite side of the plastic film surface that the nonwoven fabric is laminated with.Type: GrantFiled: September 5, 2006Date of Patent: August 13, 2013Assignee: Nitto Denko CorporationInventors: Yoshimi Yusa, Keiji Yamamoto, Tooru Kawashima
-
Patent number: 8496960Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: GrantFiled: October 23, 2002Date of Patent: July 30, 2013Assignee: Purdue Pharma L.P.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Patent number: 8491927Abstract: A pharmaceutical composition for induction therapy which has a hypomethylating agent and a histone deacetylase inhibitor (“HDAC inhibitor”); wherein the hypomethylating agent is a DNA and histone methylation inhibitor such as cladribine and the HDAC inhibitor is, for example, entinostat, panobinostat, vorinostat, and/or romedepsin; further wherein the hypomethylating agent and the HDAC inhibitor are combined in formulations for various administrations including e.g., a continuous delivery system such as a transdermal patch of at least one reservoir or a plurality of reservoirs, oral, a fixed-dose oral combination, intravenous, and combinations thereof. This pharmaceutical composition for induction therapy is used with a monoclonal antibody in the treatment of various cancers, sarcomas, and other malignancies.Type: GrantFiled: April 29, 2010Date of Patent: July 23, 2013Assignee: Nimble Epitech, LLCInventors: Elliot M. Epner, Luke M. Vaughan
-
Patent number: 8486443Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: February 4, 2004Date of Patent: July 16, 2013Assignee: Bayer IP GmbHInventors: Jochen Schuhmacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Patent number: 8486442Abstract: An external patch capable of stable prolonged release and transdermal absorption of active ingredient hormones (estrogens and/or progestogens) contained in a pressure sensitive adhesive layer, which external patch ensures low irritation on the skin. In particular, an external patch comprising a support and, superimposed thereon, a pressure sensitive adhesive layer, characterized in that the pressure sensitive adhesive layer comprises, as indispensable components, 5 to 50 wt. % of styrene/isoprene/styrene block copolymer, 20 to 70 wt. % of tackifier resin, 10 to 60 wt. % of softener and 1 to 20 wt. % of polyvinylpyrrolidone and contains, as an active ingredient, estrogen and/or progestogen.Type: GrantFiled: May 13, 2004Date of Patent: July 16, 2013Assignees: Teikoku Seiyaku Co. Ltd., Fuso Pharmaceutical Industries Ltd.Inventors: Kunihiko Matsushita, Kenichi Hattori, Masahiro Yamaji
-
Patent number: 8481071Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: May 29, 2012Date of Patent: July 9, 2013Assignee: Corium International, Inc.Inventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bairamov
-
Patent number: 8481804Abstract: A wound dressing comprising a sealed enclosure having at least one compartment; a plurality of spaced apart pillar-like structures positioned within the at least one compartment; and means for evacuating air from the at least one compartment, wherein the evacuation of air from the at least one compartment causes a reduction in the distance between at least two of the pillar-like structures.Type: GrantFiled: June 17, 2009Date of Patent: July 9, 2013Inventor: Jake Timothy
-
Patent number: 8481560Abstract: Described herein are abuse-resistant multi-layer transdermal patches comprising opioids and opioid prodrugs having a barrier layer located between the layer containing opioid or opioid prodrug and a layer containing an opioid antagonist or opioid antagonist prodrug.Type: GrantFiled: April 4, 2011Date of Patent: July 9, 2013Assignee: Alltranz Inc.Inventors: Audra Lynn Stinchcomb, Guohua Li, Stan Lee Banks, Jeffery Lynn Howard, Miroslaw Jerzy Golinski
-
Patent number: 8475837Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.Type: GrantFiled: November 23, 2010Date of Patent: July 2, 2013Assignee: Teikoku Pharma USA, Inc.Inventors: Carter R. Anderson, Russell L. Morris
-
Patent number: 8475836Abstract: Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble polymer gel, water and a water holding agent. In using the subject topical patch preparations, the topical patch preparations are applied to a skin surface of a subject and maintained at the site of application for a period of time sufficient for an effective amount of the an odorless physiological cooling agent to be administered to the subject. The subject invention finds use in a variety of applications.Type: GrantFiled: December 6, 2011Date of Patent: July 2, 2013Assignee: Teikoku Pharma USA, Inc.Inventor: Jutaro Shudo
-
Patent number: 8465759Abstract: A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.Type: GrantFiled: March 22, 2007Date of Patent: June 18, 2013Assignee: Auxilium US Holdings, LLCInventors: Michael M. Crowley, Justin M. Keen, John J. Koleng, Feng Zhang
-
Patent number: 8465763Abstract: The present invention relates to the use of 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) and/or 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3?-hydroxychlormadinone acetate and/or 3?-hydroxychlormadinone acetate.Type: GrantFiled: June 12, 2009Date of Patent: June 18, 2013Assignee: Richter Gedeon Nyrt.Inventors: Georg Schramm, Christa Kneip
-
Patent number: 8454991Abstract: The present invention relates to a photodynamic therapy method and uses thereof for treating an individual in need thereof, comprising administering a photosensitizer to an individual and activating the photosensitizer with a chemiluminescent light source, and/or a light-emitting diode light source, wherein the light source is in dermal contact with the individual. The present invention also relates to a device for photodynamic therapy comprising a permeable reservoir, for containing a photosensitizer formulation for skin application, the device is adapted to deliver the photosensitizer to the individual. The present invention also relates to a device for photodynamic therapy, comprising a permeable reservoir for containing a photosensitizer formulation for skin application and a light source.Type: GrantFiled: July 17, 2007Date of Patent: June 4, 2013Inventors: Thomas Woo, Gerald George Miller, Ragupathy Madiyalakan
-
Patent number: 8455376Abstract: An adhesive preparation comprising a stretchable support and an adhesive layer laminated on at least one side of the support, wherein the stretchable support comprises a interlock woven fabric subjected to crimping processing, the adhesive layer contains 10% by mass or more of methyl salicylate with respect to the total mass of the layer, the whole adhesive preparation has moisture permeability of 1 to 350 g/m2·24 hr measured at a temperature of 40° C. and a relative humidity of 90%, and the methyl salicylate has a plasma AUC0-24 ranging from 3.0 to 60.0 ng·hr/mL in terms of a mean±standard deviation, and salicylic acid as a metabolite of the methyl salicylate has a plasma AUC0-24 ranging from 5000 to 13000 ng·hr/mL in terms of a mean±standard deviation, when the adhesive preparation is applied to a human skin for 8 hours such that an application amount of the adhesive layer applied is 50 to 300 g/m2 and a contact area is 280 cm2.Type: GrantFiled: August 1, 2007Date of Patent: June 4, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kiyomi Tsuruda, Shinji Yamasoto, Kouki Shoho, Masaru Nakanishi
-
Patent number: 8449906Abstract: The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.Type: GrantFiled: May 2, 2011Date of Patent: May 28, 2013Assignee: EffRx Pharmaceuticals, S.A.Inventor: Christer Rosen
-
Patent number: 8449907Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: GrantFiled: July 27, 2011Date of Patent: May 28, 2013Assignee: Mylan Pharmaceuticals, Inc.Inventors: Kenneth J. Miller, II, Sharad K. Govil, Kuljit Singh Bhatia
-
Patent number: 8449908Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.Type: GrantFiled: June 20, 2005Date of Patent: May 28, 2013Assignee: Alltranz, LLCInventors: Audra L. Stinchcomb, Buchi N. Nalluri
-
Patent number: 8445010Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.Type: GrantFiled: December 22, 2010Date of Patent: May 21, 2013Assignee: Teikoku Pharma USA, Inc.Inventors: Carter R. Anderson, Russell L. Morris
-
Patent number: 8444613Abstract: A therapeutic device includes a fluid mover for one of raising, compressing, or transferring fluid, a therapeutic member operably connected to the fluid mover and actuated thereby, the therapeutic member operably disposably used on a patient in a manner to deliver therapy to the patient as function of actuation of the fluid mover, a controller operably associated with the fluid mover for controlling operation thereof, and a leak, blockage, temperature, voltage or current sensor operably connected to the fluid mover and the controller and to sense a leak, blockage, temperature, voltage or current in the device and send a signal to the controller whereby the controller controls the fluid mover as a function of the sensed signal.Type: GrantFiled: December 2, 2009Date of Patent: May 21, 2013Inventors: Pal Svedman, Tianning Xu
-
Publication number: 20130122079Abstract: A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided.Type: ApplicationFiled: July 19, 2011Publication date: May 16, 2013Inventors: James P. Dizio, Elizabeth E. Johnson, Zheng Zhi Wu, Amy Preszier Prince
-
Patent number: 8440221Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.Type: GrantFiled: September 15, 2004Date of Patent: May 14, 2013Assignee: Chrono Therapeutics, Inc.Inventors: Werner Zumbrunn, Hans Werner Van de Venn, George Imanidis, Guy DiPierro
-
Patent number: 8440220Abstract: A transdermal analgesic system having reduced potential for abuse, wherein the system provides for the controlled release of the antagonist at a rate sufficient to provide an abuse limiting release rate ratio of the antagonist to the analgesic when the dosage form is subject to abuse is disclosed.Type: GrantFiled: April 22, 2003Date of Patent: May 14, 2013Assignee: Durect CorporationInventors: Robert M. Gale, Thomas M. Stein, Jay Audett, Jane Stepic, Joseph B. Phipps, Michel J. N. Cormier
-
Patent number: 8440222Abstract: A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above.Type: GrantFiled: December 31, 2009Date of Patent: May 14, 2013Assignee: Acino AGInventors: Heike Hausner, Sebastian Braun, Heiko Spilgies
-
Patent number: 8435219Abstract: The invention relates to a self-destructing transdermal therapeutic system (TTS), preferably in the form of a transdermal patch, that includes an active ingredient, an agent rendering the active ingredient useless, and a perforation mechanism. The perforation mechanism allows a mobile phase to reach an agent that is capable of rendering the active ingredient useless after removing the TTS after use. The agent then comes into contact with the active ingredient and destroys the active ingredient in the presence of the mobile phase.Type: GrantFiled: March 26, 2009Date of Patent: May 7, 2013Assignee: LTS Lohmann Therapie-Systeme AGInventors: Stephan Maier, Margit Wirz
-
Patent number: 8435556Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.Type: GrantFiled: July 29, 2009Date of Patent: May 7, 2013Assignee: Alltranz, LLCInventors: Audra L. Stinchcomb, Buchi N. Nalluri
-
Patent number: 8431152Abstract: A transdermally absorbable preparation that even when a drug with poor solubility in a base is added in high concentration, is stable over time and can suppress crystallization of the drug, excelling in transdermal absorbability. There is provided a transdermally absorbable preparation, comprising a base and, added thereto, at least composite particles which are composed of a silicate compound and an organic acid and a drug.Type: GrantFiled: February 28, 2006Date of Patent: April 30, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Mitsuru Kuribayashi, Toshiro Yamaguchi
-
Patent number: 8425477Abstract: A system and method are provided for targeted and individualized delivery of multiple skin benefit agents to the skin of a user. The image of a predetermined treatment area of the user's skin is first captured by an imaging device. The captured image data is then analyzed by a computing device to generate a unique skin profile for the user, which is indicative of the skin conditions at the predetermined treatment area. Based on such skin profile, a printing device prints out one or more cosmetic delivery sheets that can be applied to the predetermined treatment area. Each of the cosmetic delivery sheets contains a substrate with multiple isolate, discrete regions, while at least two of the regions are imprinted with different skin benefit agents for treating different skin conditions of the predetermined treatment area according to the unique skin profile of the user.Type: GrantFiled: July 31, 2009Date of Patent: April 23, 2013Assignee: ELC Management LLCInventors: Tsung-wei Robert Mou, Fatemeh Mohammadi, Lisa Qu, Anna Czarnota, Tamar Lara Kamen